WO2000035472A3 - Cytokine combination therapy - Google Patents

Cytokine combination therapy Download PDF

Info

Publication number
WO2000035472A3
WO2000035472A3 PCT/IB1999/002001 IB9902001W WO0035472A3 WO 2000035472 A3 WO2000035472 A3 WO 2000035472A3 IB 9902001 W IB9902001 W IB 9902001W WO 0035472 A3 WO0035472 A3 WO 0035472A3
Authority
WO
WIPO (PCT)
Prior art keywords
viral
agonist
antagonist
cytokine
compounds
Prior art date
Application number
PCT/IB1999/002001
Other languages
French (fr)
Other versions
WO2000035472A2 (en
Inventor
Patrick T Prendergast
Original Assignee
Hollis Eden Pharmaceuticals
Patrick T Prendergast
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hollis Eden Pharmaceuticals, Patrick T Prendergast filed Critical Hollis Eden Pharmaceuticals
Priority to AU15797/00A priority Critical patent/AU1579700A/en
Publication of WO2000035472A2 publication Critical patent/WO2000035472A2/en
Publication of WO2000035472A3 publication Critical patent/WO2000035472A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to methods of treatment of persons and animals with indications of immuno-deficiency, wherein the said indication is resultant from viral and/or retroviral, bacterial, fungal or parasitic infection and/or plus infectious protein units. Herein is described the method of administration of an agonist or antagonist to Th2 cytokines in combination with anti-viral agents or immune enhancing agents. In one aspect of the invention, the agonist or antagonist is a receptor to Interleukin-4 (or mutein receptor) which is administered in combination with an anti-viral agent. Preferred anti-viral/immune-enhancing agents include (a) 'compounds of Formula I' (defined herein), and metabolites, analogs and precursors thereof, and pharmaceutically acceptable salts of any such compounds, metabolites, analogs and precursors, (b) protease inhibitors, and (c) reverse transcriptase inhibitors. Additionally herein is described a method of enhancing viral replication as a means of exposing latent infection by the administration of an agonist or antagonist to a Th2 cytokine. There are also provided such methods comprising administering to a patient at least one Th2 cytokine and at least one agonist and/or at least one antagonist to said Th2 cytokine. There are also provided compositions and kits for use in such methods, as well as the use of such compounds in the manufacture of medicaments for treatment for various conditions.
PCT/IB1999/002001 1998-12-15 1999-12-15 Cytokine combination therapy WO2000035472A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU15797/00A AU1579700A (en) 1998-12-15 1999-12-15 Cytokine combination therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11220698P 1998-12-15 1998-12-15
US60/112,206 1998-12-15

Publications (2)

Publication Number Publication Date
WO2000035472A2 WO2000035472A2 (en) 2000-06-22
WO2000035472A3 true WO2000035472A3 (en) 2000-11-09

Family

ID=22342651

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1999/002001 WO2000035472A2 (en) 1998-12-15 1999-12-15 Cytokine combination therapy

Country Status (2)

Country Link
AU (1) AU1579700A (en)
WO (1) WO2000035472A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8283165B2 (en) 2008-09-12 2012-10-09 Genvault Corporation Matrices and media for storage and stabilization of biomolecules
US8431384B2 (en) 2004-05-24 2013-04-30 Genvault Corporation Stable protein storage and stable nucleic acid storage in recoverable form

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553932B1 (en) 2005-04-25 2009-06-30 La Jolla Institute For Allergy And Immunology Methods of treating viral infection with IL-10 receptor antagonists

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010787A2 (en) * 1996-09-11 1998-03-19 Prendergast Patrick T Pharmaceutical compositions for the treatment of immune disorders
WO1998047516A1 (en) * 1997-04-17 1998-10-29 Prendergast Patrick T Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors
WO2000009150A2 (en) * 1998-08-17 2000-02-24 Prendergast Patrick T Cytokine and cytokine receptor, agonist, antagonist and/or antibody combination for therapeutic use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010787A2 (en) * 1996-09-11 1998-03-19 Prendergast Patrick T Pharmaceutical compositions for the treatment of immune disorders
WO1998047516A1 (en) * 1997-04-17 1998-10-29 Prendergast Patrick T Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors
WO2000009150A2 (en) * 1998-08-17 2000-02-24 Prendergast Patrick T Cytokine and cytokine receptor, agonist, antagonist and/or antibody combination for therapeutic use

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8431384B2 (en) 2004-05-24 2013-04-30 Genvault Corporation Stable protein storage and stable nucleic acid storage in recoverable form
US8283165B2 (en) 2008-09-12 2012-10-09 Genvault Corporation Matrices and media for storage and stabilization of biomolecules
US8951719B2 (en) 2008-09-12 2015-02-10 Gentegra, LLC. Matrices and media for storage and stabilization of biomolecules

Also Published As

Publication number Publication date
WO2000035472A2 (en) 2000-06-22
AU1579700A (en) 2000-07-03

Similar Documents

Publication Publication Date Title
UA40589C2 (en) method for treating a human suffering from viral infection, pharmaceutical composition, combination of compounds for the preparation of medications and pharmaceutical combination
EP0395328A3 (en) Penylpyrimidone derivates and their use as therapeutic agents
DK0688214T3 (en) Methods for Inhibiting Bone Loss with 3,4-Diarylchroman
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
SE8406538D0 (en) NOVEL DERIVATIVES OF PURINE
LU90392I2 (en) A combination comprising salmeterol optionally in the form of a pharmaceutically acceptable salt including 1-hydroxy-2-naphthoate (xinafoate) and fluticasone propionate
SE8804629D0 (en) NEW THERAPEUTICALLY ACTIVE COMPOUNDS
DE69829175D1 (en) CYCLOSPORINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS
MY102565A (en) Novel derivatives of guanine
IL90166A0 (en) Purine derivatives and use thereof in therapy
BR9910144A (en) Chemokine receptor antagonists and their use
EA200400731A1 (en) METHOD AND PHARMACEUTICAL COMPOSITION FOR UNEXPECTABLE CONTRACEPTION
BR0010593A (en) Combination therapy with pegylated ccr5-interferon alpha antagonist for hiv
ES2171440T3 (en) SOLID COMPOSITION MUCOADHESIVA, THERAPEUTICS OR HYGIENIC, FOR ADMINISTRATION BY APPLICATION ON THE MUCOSA ORAL OR NASAL.
DE50203456D1 (en) DEUTERATED 3-PIPERIDINOPROPIOPHENONE AND MEDICAMENTS CONTAINING SUCH COMPOUNDS
CA2302568A1 (en) Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
HUP0203716A2 (en) Substituted n-benzyl-indol-3-yl glyoxylic acid derivatives having an anti-tumoral effect and pharmaceutical compositions containing them
ES2051834T3 (en) THE USE OF TETRAHYDROBENZENE (C, D) INDOL-6 CARBOXAMIDES FOR THE PREPARATION OF A MEDICATION FOR THE TREATMENT OF ANXIETY.
García de Marcos et al. Localized leishmaniasis of the oral mucosa: a report of three cases
ES2001094A6 (en) Guanine derivatives.
US5179096A (en) Therapeutic application of flouroquinolone derivatives
WO2000035472A3 (en) Cytokine combination therapy
HUP0202525A2 (en) Mycophenolate mofetil in association with peg-ifn-alpha, medicaments and kit comprising thereof
Durusoy et al. Pityriasis rosea in a patient with Behcet's disease treated with interferon alpha 2A
DK122191D0 (en) BENZIMIDAZOLE DERIVATIVES AND PHYSIOLOGICALLY ACCEPTABLE SALTS AND PROCEDURES FOR THE PREPARATION OF SAME

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 15797

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase